ライフサイエンスコーパス: phenylacetate

1 ammonia scavenger drugs sodium benzoate and phenylacetate.

2 monstrated in vivo by labeling with [1-(13)C]phenylacetate.

3 bolism pathway, which led to accumulation of phenylacetate.

4 signals of the 13C-labeled anticancer agent phenylacetate.

5 recurrent malignant glioma were treated with phenylacetate.

6 These include 2,2-dibromoethyl-(2'-phenylacetate) 2 and 2-bromoethyl-(2'-phenylacetate) 3.

7 leatoxin (0.5 microM) and 12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA; 10 nM) potently induced

8 yl-(2'-phenylacetate) 2 and 2-bromoethyl-(2'-phenylacetate) 3.

9 concept that L-ornithine and phenylbutyrate/phenylacetate act synergistically to produce sustained i

10 Prostratin and DPP (12-deoxyphorbol-13-phenylacetate) activate the latent virus and thus repres

11 Phenylacetate administration decreased blood glutamine c

12 vatives, including the BN isostere of phenyl phenylacetate and BN1 triphenylmethane were prepared fro

13 er study appears to be able to catalyze both phenylacetate and p-hydroxyphenylacetate decarboxylation

14 Observations suggesting that phenylacetate and p-hydroxyphenylacetate decarboxylation

15 characterized by measuring the hydrolysis of phenylacetate and paraoxon in serum samples of 87 patien

16 The combination of intravenous sodium phenylacetate and sodium benzoate has been shown to lowe

17 ar, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyc

18 ycle disorder and treatment with both sodium phenylacetate and sodium benzoate, in conjunction with o

19 do not have a response to intravenous sodium phenylacetate and sodium benzoate.

20 nd branched ethyl esters, fatty acids, ethyl phenylacetate) and varietal compounds (4-mercapto-4-meth

21 uctural optimization of valproate, butyrate, phenylacetate, and phenylbutyrate by coupling them with

22 r of phosphomevalonate decarboxylase, sodium phenylacetate, and the protein kinase inhibitor staurosp

23 hiometric amount of dioxygen, and yields 66% phenylacetate as a product.

24 No esterase activity was detected with p-phenylacetate as the substrate.

25 oth isoforms hydrolyse chlorpyrifos-oxon and phenylacetate at approximately the same rate.

26 with an alternative route medication sodium phenylacetate/benzoate (Ucephan), or oral arginine suppl

27 Therapy with sodium phenylacetate/benzoate or sodium phenylbutyrate in urea

28 ference in the mean plasma concentrations of phenylacetate between weeks 1 and 2 or between weeks 5 a

29 bol esters prostratin and 12-deoxyphorbol-13-phenylacetate can each induce HIV ex vivo from these lat

30 arboxylic acids by FeaB, and (in the case of phenylacetate) can be further degraded to enter central

31 alcohol, methyl 3-phenylpropionate, methyl 2-phenylacetate, cinnamaldehyde and methyl cinnamate were

32 Our work reveals that a phenylacetate-CoA ligase-like enzyme Ind3 catalyzes an u

33 re that quantitatively produces toluene from phenylacetate; complementary metagenomic and metaproteom

34 in vitro characterization studies of a novel phenylacetate decarboxylase from an anaerobic, sewage-de

35 This first-time study of the phenylacetate decarboxylase reaction constitutes an impo

36 d thioesterase PaaI operative in the aerobic phenylacetate degradation pathway are examined.

37 The hybrid phenylacetate degradation pathway is encoded in Escheric

38 13 dibutyrate (PDBu) and 12-deoxyphorbol 13-phenylacetate (dPPA) elicited a rapid, and sustained, in

39 ions of 1a with tert-butyl acetate and ethyl phenylacetate enolates resulted only in hydrodehalogenat

40 (R)- and (S)-Mosher [methoxy(trifluoromethyl)phenylacetate] ester derivatives.

41 thesis, thereby detoxifying ammonia, and the phenylacetate excreting the ornithine-derived glutamine

42 Phenylacetate has little activity at this dose schedule

43 onase activity) or did not correlate at all (phenylacetate hydrolase and TBLase activities) with plas

44 n plasma-PON1 levels, determined by rates of phenylacetate hydrolysis.

45 acetate (I and II), isobutyrate (I and II), phenylacetate (II only), and indoleacetate (II only).

46 be fulfilled by the corresponding aryl acids phenylacetate, indoleacetate, and p-hydroxyphenylacetate

47 The specific incorporation of phenylacetate into phenylalanine by the IOR pathway was

48 One envelope hopanoid, bacteriohopanetetrol phenylacetate monoester, is vesicle-specific.

49 h its 5' and 3' ends to an alkylating agent (phenylacetate mustard) in an attempt to stabilize the tr

50 ine the antiproliferative activity of sodium phenylacetate (NaPa) against ovarian carcinoma cell line

51 Lovastatin and sodium phenylacetate (NaPA) were found to inhibit LPS- and cyto

52 nt study underlines the importance of sodium phenylacetate (NaPA), a drug approved for urea cycle dis

53 clohexen-1-yl)ethanone; terpinolene; ethyl 2-phenylacetate; naphthalene and 7 unknown compounds could

54 ect of ammonia-lowering treatment (ornithine phenylacetate [OP]).

55 ecreased with increasing age and with sodium phenylacetate or sodium phenylbutyrate treatment.

56 enzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenyl

57 -monoesters prostratin or 12-deoxyphorbol 13-phenylacetate, or for the macrocyclic lactone bryostatin

58 Phenylacetate (PA) is a member of a class of aromatic fa

59 A/UV/F) for measuring SPB and its metabolite phenylacetate (PA).

60 , which ruled out PaaI function in the lower phenylacetate pathway.

61 dy were to determine whether L-ornithine and phenylacetate/phenylbutyrate (administered as the pro-dr

62 Phenylacetate production rates (from phenylalanine ferme

63 The structural investigation of BN phenyl phenylacetate revealed the presence of a unique NH-carbo

64 between PON1 substrate specificity (paraoxon/phenylacetate substrate activity ratios) and -909g>c/Q19

65 nts were elicited by staurosporine or sodium phenylacetate treatment of LNCaP-Bcl-2 cells that overex

66 Phenylacetate was administered from day 19 to day 21 to

67 Purified phenylacetate was confirmed to be a neutrophil chemoattr

68 se of 400 mg/kg total body weight per day of phenylacetate was initially used and subsequently change

69 robic bacterial biosynthesis of toluene from phenylacetate was reported more than two decades ago, bu

70 ne anion 30, a synthetic equivalent of ethyl phenylacetate, was successfully employed in an alternati

71 ibitor of tumor promotion 12-deoxyphorbol 13-phenylacetate, which differs only in its side chain, ind

72 nnich-type (imino-aldol) reactions of methyl phenylacetate with N-tert-butylsulfinyl imines as the ke